home
about us
member log-in
contact us

PRODUCTS
MUNICIPAL BONDS
INDEX FUNDS
- Total Asset Fund (TAF)
EVENTS
MARKET RESEARCH

Recent Quotes

View Full List

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Ardelyx, Inc. - Common Stock (NQ:ARDX)

7.963 +0.203 (+2.61%)

Streaming Delayed Price Updated: 9:33 AM EST, Jan 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ardelyx, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Positive News For Skin Health: Aldeyra Therapeutics' ADX-629 Achieves Key Milestones in Atopic Dermatitis Study ↗

December 19, 2023

Aldeyra Therapeutics Inc (NASDAQ: ALDX) released topline results from a Phase 2 clinical trial of ADX-629, an investigational RASP modulator, in

Via Benzinga

Patient Demand Drives Ardelyx's Constipation Drug Success Amid IBS-C Treatment Gap, Says Analyst ↗

December 18, 2023

Raymond James initiated coverage of Ardelyx Inc (NASDAQ: ARDX), noting the company's two early-stage launches underway for the same molecule with differentiated pricing:

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

December 14, 2023

Via Benzinga

3 Short-Squeeze Stocks Ready for a Year-End Rally ↗

December 14, 2023

These are a few companies that have seen considerable gains this year that still have a large percentage of short interest.

Via InvestorPlace

The Latest Analyst Ratings for Ardelyx ↗

December 01, 2023

Via Benzinga

Why Ardelyx Stock Soared Today ↗

October 31, 2023

Ardelyx delivered a strong quarter thanks to solid demand for its first FDA-approved product. Here's what investors need to know.

Via The Motley Fool

Ardelyx, Inc. Reports Employment Inducement Grants

November 21, 2023

From Ardelyx, Inc.

Via GlobeNewswire

7 Penny Stocks You’ll Regret Not Buying Soon: November 2023 ↗

November 21, 2023

Unlock robust upside potential by wagering on these top penny stocks to buy in a volatile market at this time.

Via InvestorPlace

Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference

November 21, 2023

From Ardelyx, Inc.

Via GlobeNewswire

XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia

November 15, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Announces Departure of Board Member

November 13, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx to Participate at the Jefferies London Healthcare Conference

November 10, 2023

From Ardelyx, Inc.

Via GlobeNewswire

5 OTC Stocks With The Potential To Explode In 2024 ↗

November 08, 2023

Investors who are ready to dive into the OTC pool have more options than ever, both with the number of stocks to choose from and available investing platforms.

Via Benzinga

Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States

November 06, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023

November 03, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Arista Networks, JinkoSolar, Repligen, Shutterstock And Other Big Stocks Moving Higher On Tuesday ↗

October 31, 2023

U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance

October 31, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Ardelyx, Inc. Reports Employment Inducement Grants

October 30, 2023

From Ardelyx, Inc.

Via GlobeNewswire

3 Penny Stocks to Buy and Hold for the Next 10 Years ↗

October 29, 2023

These three penny stocks are the ones to buy and hold through the market conditions and the years to come for returns.

Via InvestorPlace

Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023

October 23, 2023

From Ardelyx, Inc.

Via GlobeNewswire

Tesla, Nokia And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

October 19, 2023

U.S. stock futures traded lower this morning on Thursday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Why Ardelyx Stock Popped Today ↗

October 18, 2023

Ardelyx finally received the long-awaited FDA approval for its chronic kidney disease drug.

Via The Motley Fool

Ardelyx to Report Third Quarter 2023 Financial Results on October 31, 2023

October 18, 2023

Conference call scheduled for 8:00 a.m. Eastern Time

From Ardelyx, Inc.

Via GlobeNewswire

Crude Oil Rises Sharply; Ardelyx Shares Spike Higher ↗

October 18, 2023

U.S. stocks traded lower toward the end of trading, with the S&P 500 falling more than 1% on Wednesday. The Dow traded down 0.70% to 33,760.26 while the NASDAQ fell 1.45% to 13,338.71. The S&P 500 also...

Via Benzinga

Topics Stocks

Why Nuvve Holding Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 18, 2023

Gainers Shift Technologies, Inc. (NASDAQ: SFT) shares climbed 107.8% to $0.2239. Shift Technologies recently said it will file for Chapter 11 bankruptcy protection.

Via Benzinga

Topics Bankruptcy

Abbott Laboratories, Nasdaq, Spirit AeroSystems And Other Big Stocks Moving Higher On Wednesday ↗

October 18, 2023

U.S. stocks traded lower, with the Dow Jones falling around 50 points on Wednesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Ardelyx Inc. (NASDAQ: ARDX) is One of Wednesday Morning’s Most Active Stocks

October 18, 2023

Via Investor Brand Network

Workhorse (WKHS) Stock Jumps on Drone Business Success ↗

October 18, 2023

Workhorse stock is getting a boost on Wednesday morning after providing WKHS investors with an update on its drone business.

Via InvestorPlace

FDA Sends ARDX Stock Soaring After Approving Ardelyx’s Kidney Disease Drug ↗

October 18, 2023

ARDX stock is rallying after the U.S. Food and Drug Administration (FDA) approved Ardelyx's kidney disease treatment.

Via InvestorPlace

After Initial Rejection, FDA Approves Ardelyx's Kidney Disease-Related Drug ↗

October 18, 2023

The FDA approved Ardelyx Inc's (NASDAQ: ARDX) Xphozah (tenapanor), the first and only phosphate absorption inhibitor, indicated to reduce serum phosphorus in adults with chronic kidney disease (CKD) on...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Home
About Us
Products
Municipal Bonds
Index Funds
Seminars & Events
Market Research
Contact Us
Member Section
Privacy Policy
Terms & Conditions
Security Notice
Customer Service

Securities offered through Purshe Kaplan Sterling Investments, member FINRA / SIPC, Headquartered at 80 State Street,
Albany, NY 12207
Purshe Kaplan Sterling Investments and Tamar Securities, LLC are not affiliated companies.
Tamar Securities, LLC is a Registered Investment Adviser. Advisory services are only offered to clients or prospective clients where Tamar Securities, LLC
and its representatives are properly licensed or exempt from licensure. Past performance is no guarantee of future returns. Investing involves risk and possible loss of principal capital.
No advice may be rendered by Tamar Securities, LLC unless a client service agreement is in place.

NOT FDIC INSURED. NOT BANK GUARANTEED. MAY LOSE VALUE, INCLUDING LOSS OF PRINCIPAL. NOT INSURED BY ANY STATE OR FEDERAL AGENCY.
Web development by IBCnet.com